As interest in psychedelic-assisted therapy grows, so do public questions about safety. Clinical trials of psilocybin, LSD, and MDMA often report favorable outcomes under controlled conditions, but those studies typically exclude people with complex medical histories. A new analysis of global safety data on psychedelics helps bridge the gap between tightly controlled trials and how these substances are actually used in the real world.
Researchers analyzed international pharmacovigilance reports to better understand what kinds of adverse events are being reported and how often serious physical harm occurs outside laboratory settings.
How Researchers Studied Global Safety Data On Psychedelics
The research team examined reports from VigiBase, the World Health Organization’s global database of individual case safety reports. This system collects voluntary reports of adverse events from healthcare professionals, pharmaceutical companies, and consumers across more than 180 countries.
The analysis focused on classic psychedelics including psilocybin, LSD, DMT, and mescaline, as well as MDMA, which is often grouped with psychedelics in both clinical research and recreational use. All available reports through mid December 2025 were included, creating one of the most comprehensive real world safety snapshots to date.
What The Numbers Show
Across thousands of reports, MDMA and LSD accounted for the majority of adverse event submissions. Reports involving psilocybin, DMT, and mescaline were comparatively rare, even though survey data suggests psilocybin is among the most commonly used psychedelics worldwide.
Most reports involved adults between the ages of 18 and 44, with a higher proportion of males. Importantly, psychiatric symptoms were the most frequently reported adverse events across all substances. These included anxiety, agitation, confusion, and mood disturbances.
Physical Complications Were Uncommon
One of the most striking findings from the global safety data on psychedelics was how rarely severe physical harm appeared. Reports involving cardiac, respiratory, or gastrointestinal disorders made up a small fraction of total cases. Overdose reports were also uncommon, accounting for only a small percentage of submissions for MDMA and LSD.
Pregnancy related complications and congenital abnormalities were especially rare across all substances. While these findings do not eliminate risk, they suggest that serious physiological complications are not commonly reported in real world settings.
Substance Use And Polysubstance Effects Matter
When researchers compared psychedelic reports to acetaminophen and oxycodone as control substances, an important pattern emerged. Psychedelics were more often associated with reports of substance abuse and alcohol misuse than acetaminophen, but were far less associated with classic drug dependence than oxycodone.
The authors suggest this pattern likely reflects polysubstance use. Many individuals who use psychedelics also consume alcohol, cannabis, or other recreational drugs at the same time. Because VigiBase reports lack detailed case level information, it is difficult to determine whether reported harms were caused by psychedelics themselves or by combinations of substances.
Why These Findings Matter For Patients And Clinicians
This analysis reinforces what many clinicians already suspect. Classic psychedelics appear to be physiologically well tolerated for most people, while psychiatric effects and behavioral risks deserve closer attention. The findings also highlight why real world data cannot replace individualized medical guidance.
Patients with serious psychiatric, neurological, or cardiovascular conditions should continue to avoid unsupervised use. Pregnant and breastfeeding individuals should also avoid these substances entirely.
Limitations And The Road Ahead
Because VigiBase relies on voluntary reporting, underreporting is likely. Legal concerns may also discourage people from reporting adverse effects. Despite these limitations, this study offers a valuable real world perspective that complements clinical trials.
As psychedelic-assisted therapy continues to move toward regulated clinical use, better data collection and clearer distinctions between supervised treatment and recreational use will be essential.
Citations
- Syed OA, Nestor SM, Husain MI, Sinyor M, Alam F, Giacobbe P. Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase). Psychiatry Research. 2026. PubMed entry with abstract and link: https://pubmed.ncbi.nlm.nih.gov/41485400/
- World Health Organization. VigiBase: The WHO Global Database of Individual Case Safety Reports. https://www.who-umc.org/vigibase